High Mortality and Poor Treatment Efficacy of Immune Checkpoint Inhibitors in Patients With Severe Grade Checkpoint Inhibitor Pneumonitis in Non‐small Cell Lung Cancer

Thoracic Cancer - Australia
doi 10.1111/1759-7714.13187
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Immune-Checkpoint Inhibitor Treatment of Non-Small Cell Lung Cancer Patients

Jurnal Respirasi
2020English

Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer

Cancer
Cancer ResearchOncology
2017English

P3.04-29 Efficacy of Re-Treatment With Immune Checkpoint Inhibitors in Patients With Pretreated Advanced Non-Small Cell Lung Carcinoma

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P1.01-63 Correlation Between Immune-Related Adverse Events and Efficacy of Immune-Checkpoint Inhibitors in Patients With Non-Small Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Effect of Sex on the Efficacy of Patients Receiving Immune Checkpoint Inhibitors in Advanced Non‐small Cell Lung Cancer

Cancer Medicine
Cancer ResearchNuclear MedicineRadiologyImagingOncology
2019English

Clinical Outcomes in Non-Small-Cell Lung Cancer Patients Receiving Concurrent Metformin and Immune Checkpoint Inhibitors

Lung Cancer Management
2019English

Checkpoint Inhibitors in Squamous Non-Small Cell Lung Cancer (NSCLC)

Open Access Journal of Oncology and Medicine
2018English

When to Consider Immune Checkpoint Inhibitors in Oncogene-Driven Non-Small Cell Lung Cancer?

Current Treatment Options in Oncology
OncologyPharmacology
2019English

Immune Checkpoint Modulation for Non-Small Cell Lung Cancer

Clinical Cancer Research
Cancer ResearchOncology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy